Education
About Us
Working with TipRanks
Follow Us
Taysha Gene Therapies, Inc. (TSHA)
:TSHA
TSHA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.05 - $3.31
Previous CloseN/A
Volume273.02K
Average Volume (3M)2.48M
Market Cap
$716.59M
Enterprise Value$319.32M
Total Cash (Recent Filing)$116.59M
Total Debt (Recent Filing)$61.35M
Price to Earnings (P/E)―
Beta1.89
Next Earnings
Aug 12, 2025EPS Estimate
-0.08Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.08
Shares Outstanding261,530,400
10 Day Avg. Volume2,622,657
30 Day Avg. Volume2,476,839
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.45
Enterprise Value/Revenue44.20
Enterprise Value/Gross Profit44.20
Enterprise Value/Ebitda-3.74
Forecast
1Y Price Target
$8.32Price Target Upside207.01% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyTSHA's clinical data showed a 100% responder rate on complex motor skills and communication milestones, indicating effective treatment outcomes.
Market OpportunityTSHA-102 represents an attractive commercial opportunity for the company given promising signs of clinical efficacy and a clear path to approval.
Regulatory ApprovalTSHA recently aligned with the FDA on a pivotal trial design, expected to initiate with the first patient dosed likely before year-end.
Bears Say
CompetitionCompetitors could prove difficult to beat out, and Astellas has the exclusive option to buy the program, which could limit upside.
Public PerceptionGeneral public skepticism about gene therapy presents a challenge to the adoption of TSHA-102.
Validation RisksThere are several risks to the Buy thesis, including long-term efficacy and safety needing validation, public skepticism about gene therapy, and potential competition from other companies.
Taysha Gene Therapies News
TSHA FAQ
What was Taysha Gene Therapies, Inc.’s price range in the past 12 months?
Taysha Gene Therapies, Inc. lowest stock price was $1.05 and its highest was $3.31 in the past 12 months.
What is Taysha Gene Therapies, Inc.’s market cap?
Taysha Gene Therapies, Inc.’s market cap is $716.59M.
When is Taysha Gene Therapies, Inc.’s upcoming earnings report date?
Taysha Gene Therapies, Inc.’s upcoming earnings report date is Aug 12, 2025 which is in 5 days.
How were Taysha Gene Therapies, Inc.’s earnings last quarter?
Taysha Gene Therapies, Inc. released its earnings results on May 15, 2025. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.088 by $0.008.
Is Taysha Gene Therapies, Inc. overvalued?
According to Wall Street analysts Taysha Gene Therapies, Inc.’s price is currently Undervalued.
Does Taysha Gene Therapies, Inc. pay dividends?
Taysha Gene Therapies, Inc. does not currently pay dividends.
What is Taysha Gene Therapies, Inc.’s EPS estimate?
Taysha Gene Therapies, Inc.’s EPS estimate is -0.08.
How many shares outstanding does Taysha Gene Therapies, Inc. have?
Taysha Gene Therapies, Inc. has 261,530,400 shares outstanding.
What happened to Taysha Gene Therapies, Inc.’s price movement after its last earnings report?
Taysha Gene Therapies, Inc. reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.088. Following the earnings report the stock price went up 8.017%.
Which hedge fund is a major shareholder of Taysha Gene Therapies, Inc.?
Currently, no hedge funds are holding shares in TSHA
Taysha Gene Therapies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.32 (207.01% Upside)
$8.32 (207.01% Upside)
Blogger Sentiment
Bullish
TSHA Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 94.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.4%
Last 30 Days ▲ 5.7%
Last 30 Days ▲ 5.7%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
35.64%
12-Months-Change
Fundamentals
Return on Equity
-159.34%
Trailing 12-Months
Asset Growth
-9.57%
Trailing 12-Months
Company Description
Taysha Gene Therapies, Inc.
Taysha Gene Therapies (TSHA) is a biotechnology company dedicated to developing and commercializing adeno-associated virus (AAV) gene therapies for the treatment of monogenic diseases of the central nervous system (CNS). The company's mission is to eradicate severe genetic diseases through the power of gene therapy, with a focus on advancing a robust pipeline of therapies aimed at addressing significant unmet medical needs. Taysha leverages its proprietary AAV platform and is committed to transforming the lives of patients affected by debilitating genetic disorders.
TSHA Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call was predominantly positive, with significant regulatory progress and promising clinical data on TSHA-102 for Rett syndrome. The company is financially stable with a reduced net loss and decreased R&D expenses, although there was an increase in general and administrative costs.View all TSHA earnings summariesTSHA Stock 12 Month Forecast
Average Price Target
$8.32
▲(207.01% Upside)
Technical Analysis
Cartesian Therapeutics
―
Olema Pharmaceuticals
―
Monte Rosa Therapeutics
―
2seventy bio
―
MBX Biosciences, Inc.
―
Ownership Overview
13.06% Insiders
9.45% Mutual Funds
<0.01% Other Institutional Investors
69.29% Public Companies and Individual Investors